Corpus ID: 46370969

Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical Study

@article{Satoh2015MonitoringOB,
  title={Monitoring Of Blood L-DOPA And L-DOPA Metabolite Concentrations And Adverse Events In Patients With Advanced Parkinsons Disease Receiving L-DOPA And Amantadine Combination Therapy: A Clinical Study},
  author={M. Satoh and Ami Kuzuu and H. Doi and Toru Masaka and R. Sakakibara},
  journal={Research & Reviews: Journal of Pharmacy and Pharmaceutical Sciences},
  year={2015},
  volume={4}
}
  • M. Satoh, Ami Kuzuu, +2 authors R. Sakakibara
  • Published 2015
  • Medicine
  • Research & Reviews: Journal of Pharmacy and Pharmaceutical Sciences
  • As L-DOPA replacement is the main treatment for patients with Parkinson’s disease, monitoring of the blood dopamine (DA) concentration is useful for prediction of peripheral adverse events. We studied patients with advanced Parkinson’s disease for whom L-DOPA and an NMDA receptor antagonist, amantadine, had been prescribed since 2006 at Sakura Hospital, Toho University Medical Center. The blood concentrations of L-DOPA, DA, 3,4-dihydroxyphenylacetic acid (DOPAC) and 3-O-methyldopa (3-OMD… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    Pigmentation and vision: Is GPR143 in control?
    • 7
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 17 REFERENCES
    Duration of amantadine benefit on dyskinesia of severe Parkinson's disease.
    • 230
    • Open Access
    Beneficial effects of amantadine on L‐dopa‐induced dyskinesias in Parkinson's disease
    • 195
    Pharmacokinetics of L-dopa
    • 13
    Gastroparesis and Parkinson's disease: a systematic review.
    • 93